GYRE — Gyre Therapeutics, Inc. stock price, charts and financials

QT41Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc. (NASDAQ: GYRE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
6.70
+0.03+0.45%
OverviewShort InterestFilings
GYREQT41Gyre Therapeutics, Inc.·NASDAQ
6.70+0.45%
TA
Loading chart...
Signal & projected range
QT Score upgradeHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.45%$15.46MESO+4.71%$16.69ZBIO-0.83%$32.16GHRS-1.62%$29.78TSHA-1.51%$6.46STOK-1.22%$32.31ABCL+39.97%$9.70VRDN-3.29%$22.81
Snapshot
Index-P/E-EPS (ttm)-0.52Insider Own-Shs Outstand91.39MPerf Week16.00%
Market Cap609.58MForward P/E-EPS next Y-0.10Insider Trans-0.18%Shs Float16.64MPerf Month-2.77%
Enterprise Value569.71MPEG-EPS next Q-Inst Own-Short Float2.24%Perf Quarter-5.66%
Income-16.70MP/S5.11EPS this Y44.23%Inst Trans-Short Ratio21.70Perf Half Y-11.19%
Sales119.38MP/B6.22EPS next Y65.52%ROA-9.23%Short Interest2.04MPerf YTD-5.52%
Book/sh-P/C-EPS next 5Y-ROE-17.63%52W High9.46 -29.19%Perf Year-4.99%
Cash/sh-P/FCF141.04EPS past 3/5Y-9.14% -ROIC-9.69%52W Low5.46 22.61%Perf 3Y27.05%
Dividend Est.-EV/EBITDA-Sales past 3/5Y4.68% 40.99%Gross Margin94.30%Volatility5.09% 4.66%Perf 5Y-89.07%
Dividend TTM-EV/Sales4.77EPS Y/Y TTM-1140.00%Oper. Margin-13.97%ATR (14)0.31Perf 10Y-98.01%
Dividend Ex-DateJan 13, 2023Quick Ratio3.86Sales Y/Y TTM-1.89%Profit Margin-15.41%RSI (14)59.79Recom2.00
Dividend Gr. 3/5Y-Current Ratio4.26EPS Q/Q-SMA208.97%Beta2.34Target Price17.00
Payout0.00%Debt/Eq0.03Sales Q/Q4.55%SMA507.44%Rel Volume0.75Prev Close6.67
Employees625LT Debt/Eq0.01EarningsNov 18SMA200-8.04%Avg Volume90.14KPrice6.70
IPO DateApr 12, 2006Option/ShortYes / YesEPS/Sales Surpr.31.82% -28.75%Net Debt/EBITDA2.84Volume67,602Change0.45%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-10-25InitiatedJefferiesBuy$16
Aug-26-25InitiatedH.CBuy$18
Latest News
Company

Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue120117106——————
Cost of Goods Sold Incl. D&A754——————
Gross Profit112111102——————
Selling, General and Administrative Excl. Other948674——————
Research and Development281412——————
Other Operating Expense
700——————
Operating Income-161116——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)137——————
Net Income Before Taxes-151423——————
Income Taxes255——————
Consolidated Net Income-19512——————
Net Income From Continuing Operations-161018——————
Net Income-19512——————
EPS (Recurring)-0.200.060.14——————
EPS (Basic, Before Extraordinaries)-0.200.060.14——————
EPS (Diluted)-0.200.020.05——————
EBITDA-141718——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio—313.78242.00——————
Price To Sales Ratio5.645.379.70——————
Gross Margin93.3394.8796.23——————
Operating Margin-13.339.4015.09——————
Net Margin-15.834.2711.32——————
Shares Outstanding1018985——————
Market Capitalization6776281,029——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$10.05$8.78$7.51$6.24$4.97● Close Price0.00K115.41K230.82K346.23K461.64KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Ye WeiguoChief Operating OfficerJun 18 '26Sale6.353,00019,050700,000Jun 22
Ye WeiguoChief Operating OfficerJun 18 '26Option Exercise0.753,0002,250703,000Jun 22
Ye WeiguoChief Operating OfficerJun 10 '26Option Exercise0.7511,4188,564706,418Jun 22
Ye WeiguoChief Operating OfficerJun 10 '26Sale6.2211,41871,056700,000Jun 22
Ye WeiguoChief Operating OfficerJun 09 '26Sale6.1417,500107,480700,000Jun 22
Ye WeiguoChief Operating OfficerJun 09 '26Option Exercise0.7517,50013,125835,701Jun 22
Ye WeiguoChief Operating OfficerJun 11 '26Option Exercise0.752,8002,100702,800Jun 15
Ye WeiguoChief Operating OfficerJun 11 '26Sale6.172,80017,276700,000Jun 15
Ye WeiguoChief Operating OfficerJun 05 '26Option Exercise0.7515,40111,551715,401Jun 08
Ye WeiguoChief Operating OfficerJun 05 '26Sale6.4015,40198,566700,000Jun 08
Ye WeiguoChief Operating OfficerJun 04 '26Option Exercise0.7519,57514,681719,575Jun 08
Ye WeiguoChief Operating OfficerJun 04 '26Sale6.1319,575119,995700,000Jun 08
Ye WeiguoChief Operating OfficerMay 26 '26Option Exercise0.754,0003,000704,000May 27
Ye WeiguoChief Operating OfficerMay 26 '26Sale6.104,00024,400700,000May 27
Ye WeiguoChief Operating OfficerMay 22 '26Option Exercise0.753,5002,625703,500May 27
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.